There is currently no warning information available for this product. We apologize for any inconvenience.
There is currently no manufacturer warning information available for this drug.
Cormax Ointment is indicated for short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
This product is not recommended for use in pediatric patients under 12 years of age.
Cormax Ointment contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.
Chemically, clobetasol propionate is 21-Chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione,17-propionate and it has the following structural formula:
Clobetasol propionate has the molecular formula C
25H
32ClF0
5 and a molecular weight of 467. It is a white to cream-colored crystalline powder insoluble in water.
Each gram of Cormax Ointment contains 0.5 mg clobetasol propionate in a base composed of propylene glycol, sorbitan sesquioleate, and white petrolatum.
